Double purse-string telescoped pancreaticogastrostomy is not superior in preventing pancreatic fistula development in high-risk anastomosis: a 6-year single-center case–control study

2021 ◽  
Author(s):  
Jonathan Garnier ◽  
Jacques Ewald ◽  
Ugo Marchese ◽  
Anais Palen ◽  
Djamel Mokart ◽  
...  
Keyword(s):  
High Risk ◽  
Pancreatic Fistula ◽  
Case Control Study ◽  
Case Control ◽  
Single Center ◽  
Purse String ◽  
Control Study

scholarly journals TruScreen detection of cervical tissues for high-risk human papillomavirus–infected women during the coronavirus disease 2019 pandemic

2020 ◽  
Author(s):  
Ziyao Wang ◽  
YaNan Kang ◽  
FuRong Yu ◽  
Feng-Hui Zhong ◽  
Kangni Huang ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Case Control Study ◽  
Screening Method ◽  
Case Control ◽  
Single Center ◽  
Cervical Lesions ◽  
Positive Results ◽  
Control Study ◽  
Prospective Case Control Study

Objectives: To evaluate the efficacy of TruScreen (TS01) for high-risk human papillomavirus (HR-HPV) women compared with other methods in reducing colposcopy referral rates in hospitals. Methods: A single-center, prospective, case–control study was conducted from December 2019 to June 2020. Results: Among 139 (46.2%) HR-HPV positive patients, 58 were CIN1, 52 were CIN2-3 and 29 had cervical cancer (n = 29). The sensitivity and specificity of detecting CIN2+ by TS01, colposcopy and HPV16/18 testing were 96.3% and 46.4%, 85.2% and 40.5% and 59.3% and 74.1%, respectively. The highest sensitivity was 96.3% at HPV16/18 and TS01 (each positive results), and the highest specificity was 83.6% at HPV16/18 and TS01 (both positive) for CIN2+ compared with the other methods. Conclusion: TS01 is a noninvasive screening method and can be used to diagnose cervical lesions quickly. It is especially suitable as triage tool for HR-HPV-positive women facing SARS-Cov-2 exposure and infection risks in hospital.

Does Placental Weight Affects Perinatal Outcome? A Prospective Case-control Study

2020 ◽  
Vol 16 (1) ◽  
pp. 52-59
Author(s):  
Naina Kumar ◽  
Himani Agarwal
Keyword(s):  
Birth Weight ◽  
High Risk ◽  
Perinatal Outcome ◽  
Case Control Study ◽  
Neonatal Outcome ◽  
Case Control ◽  
Placental Weight ◽  
Tertiary Center ◽  
Control Study ◽  
Prospective Case Control Study

Background: Placenta plays a very important role in the growth and development of fetus. Objective: To know the correlation between placental weight and perinatal outcome in term antenatal women. Methods: Present prospective case-control study was conducted in the rural tertiary center of Northern India over one year (January-December 2018) on 1,118 term (≥37-≤42 weeks) antenatal women with singleton pregnancy fulfilling inclusion criteria with 559 women with high-risk pregnancy as cases and 559 low-risk pregnant women as controls. Placental weight, birth weight was measured immediately after delivery and compared between the two groups along with gestation, parity, fetal gender, and neonatal outcome. Statistical analysis was done using SPSS 22 version. Results: Mean placental weight [481.98±67.83 gm vs. 499.47±59.59 gm (p=.000)] and birth weight [2.68±0.53 Kg vs. 2.88±0.4 Kg (p=.000)] was significantly lower in high risk as compared to lowrisk participants, whereas placental birth weight ratio was higher in high-risk cases [18.35±2.37 vs. 17.41±1.38 (p=.000)] respectively. Placental weight was positively correlated with birth weight and placental weight and birth weight increased with increasing gestation in both cases and controls. Male neonates had higher placental weight [492.74±68.24 gm vs. 488±58.8 gm (p=0.224)] and birth weight [2.81±0.5 Kg vs. 2.74±0.45 Kg (p=0.033)] as compared to females. Neonatal Intensive Care Unit admission was significantly associated with low placental and birth weight (p=.000). Conclusion: There is a significant correlation between placental weight, birth weight and neonatal outcome, hence placental weight can be used as an indirect indicator of intrauterine fetal growth.

Outcomes of elective left colectomy in renal-transplanted patients: a single-center case-control study (LECoRT study)

2021 ◽  
Author(s):  
Thomas Bardol ◽  
Regis Souche ◽  
Diane Genet ◽  
Charlotte Ferrandis ◽  
Françoise Guillon ◽  
...  
Keyword(s):  
Case Control Study ◽  
Case Control ◽  
Single Center ◽  
Left Colectomy ◽  
Control Study

scholarly journals Tolerability of Bowel Preparation and Colonoscopy in IBD Patients: Results From a Prospective, Single-Center, Case–Control Study

2020 ◽  
Vol 2 (4) ◽  
Author(s):  
Cristina Bezzio ◽  
Mario Schettino ◽  
Gianpiero Manes ◽  
Paolo Andreozzi ◽  
Ilaria Arena ◽  
...  
Keyword(s):  
Bowel Preparation ◽  
Analogue Scale ◽  
Case Control Study ◽  
Screening Program ◽  
Case Control ◽  
Single Center ◽  
Split Dose ◽  
Inflammatory Bowel ◽  
Control Study ◽  
Demographic Features

Abstract Background Endoscopy plays a fundamental role in the management of patients with inflammatory bowel disease (IBD). The aim of this study was to prospectively evaluate the tolerability and efficacy of bowel preparation and colonoscopy in ulcerative colitis (UC) and Crohn’s disease (CD) patients compared to subjects participating in a colorectal cancer population screening program. Methods Consecutive enrolment of CD and UC patients and screening subjects (SS) undergoing colonoscopy. Bowel preparation was done by split dose of 2 L PEG-ELS + simethicone. We recorded endoscopic, clinical, and demographic features; cleanliness rating using the Boston Bowel Preparation Scale (BBPS); and sedation doses. Bowel-preparation tolerability, discomfort, and pain during colonoscopy were assessed using a Visual Analogue Scale from 0 to 100 mm. Results Sixty-three UC (mean age 49.9 ± 14.9 years), 63 CD (mean age 44.0 ± 14.0 years), and 63 SS (mean age 59.9 ± 6.3 years) patients were enrolled. Bowel preparation was similarly tolerated in UC, CD, and SS (P = 0.397). A complete colonoscopy was similarly performed in UC (59/63, 93.7%), CD (58/63, 92.1%), and SS (60/63, 95.2%) (P = 0.364). The BBPS did not show significant differences between UC (6.2 ± 1.6), CD (6.1 ± 1.3), and SS (6.2 ± 1.4) (P = 0.824). The need to increase sedation doses was significantly higher in CD (24/63, 38.1%) and UC (16/63, 25.4%) than in SS (4/63, 6.3%) (P < 0.0001). Conclusions Bowel preparation is equally tolerated and efficacious in IBD patients and in healthy SS. In IBD, higher sedation doses are needed to guarantee an equally tolerated colonoscopy.

scholarly journals Risk factors of acute diarrhoea in summer – a nation-wide French case-control study

2000 ◽  
Vol 124 (3) ◽  
pp. 409-416 ◽  
Author(s):  
Y. YAZDANPANAH ◽  
L. BEAUGERIE ◽  
P. Y. BOËLLE ◽  
L. LETRILLIART ◽  
J. C. DESENCLOS ◽  
...  
Keyword(s):  
Risk Factors ◽  
High Risk ◽  
Case Control Study ◽  
National Level ◽  
Acute Diarrhoea ◽  
Case Control ◽  
French Case ◽  
Risk Areas ◽  
Matched Case ◽  
Control Study

The aim of this study was to identify risk factors for acute diarrhoea (AD) during the summer in France. A matched case-control study was conducted at a national level among patients of 500 general practitioners (GPs). From July to September 1996, 468 case-control pairs were included. Cases were more likely than controls (i) to live away from their main residence (OR 3·0; 95% CI 1·6–5·7), (ii) to have returned from a country at high risk of AD (OR 4·6; CI 0·9–23·1), and (iii) to have been in contact with a case of AD (OR 2·0; CI 1·3–3·1). A significantly decreased risk of AD was found for consumption of well-cooked chicken (OR 0·5; CI 0·3–0·8) and raw or undercooked home-made egg-containing products (OR 0·6; CI 0·4–0·8). These findings suggest that travel to high-risk areas, or travel within France, and being in contact with a case of AD, are risk factors for the occurrence of AD in summer in France.

Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 10531-10531
Author(s):  
Anosheh Afghahi ◽  
Sydney Marsh ◽  
Alyse Winchester ◽  
Dexiang Gao ◽  
Hannah Parris ◽  
...  
Keyword(s):  
Lymph Node ◽  
Genetic Testing ◽  
High Risk ◽  
Case Control Study ◽  
Case Control ◽  
Low Risk ◽  
Mutation Status ◽  
T Stage ◽  
Chek2 Mutation ◽  
Control Study

10531 Background: Genomic assays, such as RS, are used to determine chemotherapy benefit in early-stage, estrogen receptor (ER)- and/or progesterone receptor (PR)-positive, HER2 negative BC patients (pts). Currently, guidelines to use pts’ germline genetic testing results to guide adjuvant therapy are lacking. Several reports have indicated worse outcomes for BC pts with g CHEK2 pathogenic variants (PV). We investigated whether PV in CHEK2 were associated with increased RS. Methods: Patient-level clinical data and RS were derived from electronic medical records of seven medical centers between years 2013-17. Confirmation of RS using the Genomic Health provider portal was performed. 38 pts with germline PV in CHEK2 (15 pts/39.5% with c.1100delC mutation) and RS score (cases) were matched with BC pts whose genetic testing did not identify PV (controls) using a 1:2 matching schema. Pts were matched based on age at diagnosis and lymph node (LN) status. LN negative pts were further matched based on T-stage. A multivariate random intercept linear mixed model of CHEK2 mutation status on RS was performed, adjusting for PR. A secondary ordinal univariate analysis was conducted that categorized RS into low, intermediate and high risk ( < 18, 18-30, and > 30, respectively). P-values were reported based on a null hypothesis of no effect against a two-sided alternative. Results: The median RS for cases was 19.5 (interquartile range [IQR]: 15 to 25) and the median RS for controls was 18 (IQR: 12 to 22). A greater proportion of cases were categorized as high risk (10.5%) compared to controls (5.6%), and a smaller proportion of cases were categorized as low risk (36.8%) compared to controls (49.3%). Cases had higher grade and increased proportion of PR-negative BC as compared with controls (grade 1: 12.1% of cases versus 32.4% of controls; PR-negative: 7.9% of cases versus 5.6% of controls). The variables used to match cases and controls (age, lymph node status, and T-stage) had similar summary statistics. The RS was 1.97-point higher in pts with g CHEK2 PV compared to controls, after adjusting for PR (95% confidence interval [CI]: 1.02-point lower to 4.96-point higher; p = 0.194). The secondary analysis of CHEK2 mutation status on an ordinal RS risk group yielded comparable results; on average, the odds of being high risk compared to the combined intermediate/low risk groups was 1.72 times higher in cases compared to controls (95% CI: 0.77 to 3.80; p = 0.181), but these differences were not significant. Conclusions: Our case-control study did not show a statistically higher RS for BC that develops in pts with g CHEK2 PV. Further studies are warranted to evaluate the association between type of CHEK2 PV (frameshift versus missense) and other modifying genetic variables and RS.

Sign in / Sign up

Export Citation Format

Share Document